Syndicate content

Gene Signature Associated with Gleevec Resistance in GIST Patients

A genetic signature associated with increased resistance to Gleevec in patients with gastrointestinal stromal tumors (GIST) has been identified by researchers at the Fox Chase Cancer Center. Efforts to affect the expression and/or activity of genes in the signature may help increase the responsiveness to Gleevec in resistant patients. Currently, approximately 80% of GIST patients are responsive to Gleevec. This work was presented at the annual AACR meeting April 18-22. [Press release]